Company intelligence / Profile preview

Endologix

Irvine, California, United Statesendologix.com ↗

Ownership: Public · ELGX
Employees: ~201
Development stage: Other

Overview

Endologix has multiple FDA-approved and CE-marked devices for the minimally invasive treatment of abdominal aortic aneurysms and peripheral vascular diseases. Its flagship products include the ALTO® Abdominal Stent Graft System and DETOUR® System. The company’s solutions are supported by clinical evidence and are commercially available in several markets.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Financials

Market cap: $181.4M
Total revenue: $0
Enterprise value: $180.4M

Beyond the preview

Go deeper on Endologix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endologix.

Explore the full profile